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Abstract
Objective-To understand whether previ-
ous styrene exposure increases the human
liver's ability to convert styrene into
styrene oxide.
Methods-The hypothesis was tested that
the average linear metabolic rate constant
K was the same in both exposed and unex-
posed groups, when the exposed group
comprised people with a history of
styrene exposure and the unexposed
group had no exposure. In an experimen-
tal chamber, these two groups of subjects
were exposed to a concentration of 80
ppm styrene for two hours. A three com-
partment pharmacokinetic model was
used to define ic. Based on large sample
theory, the comparison of estimated
mean values of K in the exposed and unex-
posed groups was shown to be equivalent
to a comparison of the estimated mean
values of the hepatic clearance X in the
two groups. A method was developed to
estimate X for each subject in both groups
from the subject's height, weight, and
estimated asymptotic styrene decay con-
stant a. Here, a was estimated individu-
ally from observed blood concentrations
over time when sufficient time had
elapsed after the controlled exposure.
Results-The proposed methodology of
comparing the estimated mean values of K
in exposed and unexposed groups reduced
the number of specific physiological vari-
ables involved to three, all of which were
estimable from data based on simple
direct measurements. In contrast, other
methods based on pharmacokinetic mod-
els usually involved many variables that
were non-estimable on an individual
basis. Consequently, statistical compar-
isons were impossible. These methods
were applied to analyse previously pub-
lished data on the time course of styrene
concentrations in arterial blood of sub-
jects in both exposed and unexposed
groups. A Wilcoxon non-parametric rank
sum test with the individually estimated X
values was used, and no significant differ-
ence in the means ofX in the two groups
was found.
Conclusion-The linear metabolic rate
constant K for humans is probably not
altered by previous exposure to styrene.
This result is in agreement with some
experimental studies on animals.
However, in the data analysis, it was
noted that the number of subjects in each
group was small (6-7) and that the styrene
concentration data did not exactly reflect
true behaviour of asymptotic decay.
Further studies are still needed to draw
more definitive conclusions.
(Occup Environ Med 1996;53:601-605)
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Most genotoxic effects of styrene are likely to be
due to styrene-7,8-oxide (SO),' which is a labile
intermediate metabolite of styrene activated by
microsomal enzymes.2 This is subsequently
detoxified into styrene glycol,'2 which is then
oxidised to mandelic acid and phenylglyoxylic
acid,3 both of which are excreted in urine.
There is speculation that previous exposure to
styrene may induce CP450 enzymes and
thereby increase the biotransformation of
styrene into SO. Andersen et at4 found that the
blood styrene concentrations were lower in rats
that had been previously exposed to styrene.
From this they reasonably concluded that
styrene induced its own metabolism. Elovaara
et al5 showed that styrene metabolism in vitro
by liver microsomes was greatly increased after a
period of exposure to styrene (2100 mg/M3 for
24 hours) in rats. On the other hand, Mendrala
et a16 found that monooxygenase activity was
not changed in liver microsomes of rats and
mice that had been exposed for six hours a day
for three days to 600 ppm styrene. Likewise,
Filser et at7 exposed rats and mice to 150 and
500 ppm styrene on five consecutive days (6
h/day) and found no change in the rate of
styrene metabolism compared with non-pre-
treated controls.
Unlike in animal studies, direct measure-
ments of metabolic activity are difficult to make
in humans. This paper develops the theoretical
framework for testing the null hypothesis that
the average level of metabolic activity is the
same in groups with and without previous expo-
sure to styrene. Then the methods are evaluated
with data from Wigaeus et al and LUf et at,89
who exposed groups of people with and without
previous exposure to styrene at 80 ppm for two
hours in an exposure chamber. Arterial concen-
trations of styrene were measured both during
and after exposure. To measure the level of
metabolic activity, we present a three compart-
ment pharmacokinetic model to simulate the
uptake, distribution, metabolism, and elimina-
tion of styrene and to define the linear metabolic
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mean value of ic in each group is proportional to
the estimated mean value of the hepatic clear-
ance X (defined in equation (6)) in that group.
When the number of subjects in each group is
large, the proportionality constants for the two
groups become close to one another.
Consequently, for large samples, we can test our
null hypothesis through a comparison of the
estimated mean values of X.
Normally, to estimate iK and other variables,
the use of a physiologically based pharmacoki-
netic model requires detailed information, such
as tissue blood flow rate, cardiac output, tissue
volume, ventilation, styrene concentration in
blood over time, etc. Unfortunately, most of
these input variables are not directly measurable
and are replaced by some standard values that
are not specific to each person (see table 3). As a
result, variables like iK are generally not uniquely
estimated, and hence the precision of such esti-
mates is unknown. Our proposed methodology
avoids many of these drawbacks. We derive a
simple estimator for X from the asymptotic
behaviour of the styrene concentration in blood
after exposure. This estimator involves only
three estimable physiological variables specific
to each person, namely, height, weight, and the
asymptotic decay constant a, where a is esti-
mated from the decay of styrene concentrations
in blood after the end of exposure.
Methods
DESCRIPTION OF THE MODEL
We assume that the metabolism of styrene
takes place exclusively in the liver, although
some studies suggest that pulmonary tissues
and bone marrow may also participate to a
small degree.'0 Under moderate physical exer-
cise, the skin and muscle tissues become well
perfused, as do blood vessel rich tissues like
the brain, kidney, and viscera. Therefore, the
body tissues can be roughly grouped into lean
tissues (i = 1), fatty tissues (i = 2), and the
liver (i = 3) (figure). We assume that each
type of tissue has similar composition-that is,
the percentages of lipid and water-and simi-
lar blood perfusion, and can, therefore, be
characterised by a single tissue/blood partition
coefficient & and a single blood flow rate Q (in
I/min). Throughout this paper, unless other-
wise specified, time is in minutes, volume in
litres, and concentration in mg/l.
For i = 1 and 2, we have a simple mass bal-
ance equation:
dC(t) Q~r Ci(t) (1--j) [Can('t) - I, (1)
dt 1< L k
where Ci(t) and Car,(t) are, respectively, the
styrene concentration in the i-th tissue group
and in the arterial blood, and where V, is the
effective volume of the i-th tissue group. For
the liver, we have an additional term to repre-
sent the metabolism of styrene:
dC3(t)QN rC.IN C (1-KC3C)
dt v~I a At3__ (2)
Metabolites
Physiologically based three compartment model. Under moderate physical exercise, the body
tissues can be grouped into well perfused tissues (lean tissues), poorly perfused tissues (fatty
tissues), and the liver (the main metabolising organ). The time dependent behaviour of
styrene concentration in blood is determined by a set of differential equations based on mass
conservation. These equations involve the physiological variables shown here.
where the metabolic rate has been assumed
to be first order, as characterised by the con-
stant K (min-).
ASYMPTOTIC VARIABLES
During the period after exposure, the blood
concentration is found to decline in two
phases: a first distribution phase, in which
concentrations of styrene in all tissues except
the fat come into rough equilibrium with the
arterial blood concentration, and a second
phase, in which the primary mechanism of the
decay is metabolism. Once equilibrium
throughout the body tissues has been more or
less established, the whole body can be treated
as a single compartment." Then the equation
of conservation of mass gives:
dt VA= AalbC-n(t)Qr K-V3AgCart(t) (3)
where Qr denotes the alveolar ventilation
and Ab the air/blood partition coefficient.
We solve this equation for Car,(t) to obtain:
C.,n(t) = Coexp ( -ox) (4)
where C0 is a constant independent of t, and
where:
a = Ag/bQaar + KV33, (5)
zVx.
is the decay constant for styrene concentra-
tion in blood. We can estimate a by fitting
602
Comparison of average estimated metabolic rates for styrene in previously exposed and unexposed groups with pharmacokinetic modelling
Table 1 Styrene concentration (,umol/l) in arterial blood at various times (min) after 2-hour exposure to 80 ppm styrene for groups with and without
earlier exposure to styrene (heights and weights of all subjects are presented)
Group without earlier exposure to styrene Group with earlier exposure to styrene
Time 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8
75 1-45 1-29 - 2-97 3-91 2-85 2-86 1-94 1-17 2-2 1 91 2-0 3-92 3-33 1-44 1-54
90 1-1 0-82 - 3-28 2-15 2-65 2-16 1-36 1-14 1.91 2-34 2-13 2-6 1-92 1-39 1-38
105 1-16 1-01 - - 1-69 2-02 - 2-09 1-38 - 1-23 1-27 2-38 1-92 0-71 1-33
120 0-45 0-53 - 2-44 1-35 1-45 1-4 1-76 0-77 1-78 1-25 1-09 1-56 1-29 0 9 1-35
180 0 35 0-51 - 1-42 1-52 1-49 1 2-41 - - - - - - - -
240 0 54 0-38 - 1-2 1-04 0-82 0-98 1-07 - - - - - - - -
Height (m) 180 178 180 174 178 191 172 179 182 174 188 173 176 170 180 179
Weight (kg) 80 68 70 72 60 79 68 67 69 72 105 74 72 69 68 78
equation (4) to the final portion of the decay
curve with least squares method. Note that the
styrene concentration in arterial blood should
be equal to that in the venous blood after equi-
librium is reached. With this estimated d we





(note that the hepatic clearance defined in
(6) is not the "apparent clearance" defined in
Wigaeus et al8). As the partition coefficient .1
(adipose tissue/ blood) is about 50 times as
large as AX (lean tissue/blood) and is over 4000
times as large as .,b (see table 3)3, the domi-
nant contribution in equation (7) comes from
the adipose tissues. Hence:
XI d 22 (8)
STATISTICAL COMPARISON
Suppose we have a random sample of subjects
of size ni from the j-th group, where j = 1 per-
tains to the group with previous exposure to
styrene and j = 2 to the previously unexposed
group. All physiological variables vary from
person to person. In a sense, each such vari-
able can be considered to have a distribution
determined by its varying values across a popu-
lation of subjects. For subject k (k = 1,..., ni;
= 1,2), we can estimate the hepatic clearance
Xk(j) according to equation (8). The unbiased
estimators of the mean and variance of the
underlying distribution of hepatic clearance
values for the j-th population are:
Table 2 Estimates of the decay constant d (min '), adipose tissue volume V2 (7), and the
hepatic clearance X (1/min) of all subjects in groups with and without earlier exposure to
styrene
Group with earlier exposure Group without earlier exposure
Subject V2 d l V2 d l
1 8-4 0-0053 3-1 24-2 0-0072 12-3
2 17-5 0-0046 5-6 9 7 0-0068 4-6
3 52-0* 0-0116 42-8 11-0 - -
4 20-8 0-0132 19-4 17-5 0-0067 8-2
5 16-2 0-0193 22-2 -0 9* 0-0025 -
6 16-1 0-0208 23-7 15-7 0-0051 5-6
7 8-4 0-0142 8-4 13-5 0 0033 3-1
8 22-2 0.003 4-7 7-7 0-0027 1-4
Mean 15 7t 0-0115t 12-7t 14-7$ 0-0053t 55*:
*The estimate may not be valid because the subject's height or weight are outside the range over
which the regression model (12) is constructed.
tSubject 3 is excluded.
tSubjects 3 and 5 are excluded.
E(X(j)) 1 X) (9)
k=I
nj
V(X()) = 1 X* - E(X(0)))] 2 (10)
where j = 1,2.
As the linear metabolic rate constant K mea-
sures the proportion of the amount of styrene
in a unit volume of liver that can be converted
to SO in a unit of time, it is therefore indepen-
dent of the liver's volume V3. From equation
(6), we obtain:
E(K(O)) = TXO (I11)
where j = 1, 2, and where it is assumed that
K and V3 are independent for each subject. If nj
(j = 1,2) is large, we expect that both
E(V3(1)) and E(V3(2)) would approach the
common population mean E(V3). Con-
sequently, a comparison of the means of the
metabolic rate constants in the two groups can
be made through a comparison of the corre-
sponding means of the estimated hepatic
clearances. When sample sizes are small, the
above statement is still approximately correct
if one can ignore any difference in the means
of V3 in the two groups.
STUDIES OF PEOPLE WITH AND WITHOUT
PREVIOUS EXPOSURE
Wigaeus et at8 and L6f et at9 carried out a
study to compare, among other things, the
concentration of styrene in arterial blood
between groups with and without previous
styrene exposure. The unexposed group was
composed of eight healthy male volunteers
without a history of styrene exposure, whereas
the exposed group was composed of eight
workers routinely exposed to styrene. All sub-
jects in both groups were exposed to styrene at
a concentration of 80 ppm for two hours during
light physical exercise at a work load of 50 W.
The concentration of styrene in arterial blood
was measured several times for each subject
during and after styrene exposure. Each sub-
ject's height and weight were also measured.
Table 1 shows the raw data that are used in
this investigation.
Results
Table 2 shows the estimated adipose tissue
volume V2, decay constant , and clearance X
for each subject in the two groups. V2 is esti-
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Table 3 Data used in the standard pharmacokinetic model
Rest Workload 5OW
Total cardiac output (1/min): Q 6 0 19 9.9 20
Local blood flow to tissue group 1 (1/min): Q 4-1 19 8-0*
Local blood flow to tissue group 2 (1/min): Q2 0-32 19 0-32*
Local blood flow to tissue group 3 (1/min): Q3 1-5 1.5*
Volume of tissue group 1 (1): VI 3'1 37-3 37-3
Volume of tissue group 2 (1): V219 14-5 14-5
Volume of tissue group 3 (1): V3 3 1-7 1-7
Tissue/blood partition coefficient for group 1: Xi 3 1-2 1-2
Tissue/blood partition coefficient for group 2: X23 71-0 71-0
Tissue/blood partition coefficient for group 3: 33 2-6 2-6
Air/blood partition coefficient: X.,3 1/59 1/59
Alveolar ventilation(l/min): Qir 4.9 20.0 20
*Assume that the excess cardiac output relative to the rest state will only go to the muscle group.
mated based on a person's height H (m) and
weight W (kg) according to the formula:
12 = 1-32(W - 26 69HI424) (12)
This estimator is based on a modification of
DMbeln's work,'2 where the product of the
sums of right and left femoral condylar
breadth and bistyloid radioulnar breadth were
replaced by a constant; the factor 1 32 is used
to convert the amount of fat (kg) to the corre-
sponding volume (1). The decay constant a for
each subject is estimated by fitting equation
(4) to the observed blood concentration decay
curve from t = 75 to 120 minutes (three to
four data points) for the treatment group and
from 90 to 240 minutes (four to five data
points) for the control group. The clearance is
estimated with equation (8), with the partition
coefficient ., taken from table 3.
As we are not willing to make any assump-
tions about underlying population distribu-
tions and as group specific sample sizes are
small, we used a Wilcoxon non-parametric
rank sum test to test for a significant difference
in the means of the estimated clearance values
in the two groups. We obtained a P value of
0-17, implying that the difference in the esti-
mated means ofX in the two groups is not sig-
nificant. Note that the P value for a two
sample t test is 0-12 (variances are not signifi-
cantly different between the two groups: P =
0.09), which is in agreement with the non-
parametric Wilcoxon test. In both tests, we
excluded subject 3 (adipose tissue volume was
not estimable from equation (12)) in the
group with previous exposure, and subjects 3
(experimental data was not available to allow
estimation of a) and 5 (adipose tissue volume
was not estimable from equation (12)) in the
group without previous exposure. Therefore,
the total number of subjects were seven and
six in the groups with and without previous
exposure to styrene, respectively.
Discussion
Filser et a17 showed that linear metabolism was
operative in rats and mice exposed to styrene
up to 1 28 mg/l (300 ppm). Mendrala et a16
estimated the maximum rate of metabolism
Vmax (mg/min) and the Michaelis-Menten con-
stant Km (mg/i) in humans, in vitro. In that
case, the estimate of K,,, was 9 4 mg/I. LUf and
Johanson"3 showed that metabolic saturation
did not occur at concentrations below 250
ppm styrene (1-06 mg/i) in human volunteers.
Therefore, equation (2) is appropriate for the
subjects in our comparison who were exposed
to 80 ppm of styrene. However, if the expo-
sure concentration was higher than about 250
ppm of styrene, the equation would be modi-
fied to account for saturable metabolism; that
is:
dC3(t) = T3 C.(t) - C3(t)1 VmoxC3( ) (13)
dt /13J V3(Km+C3(t))




no longer holds and equations (4)-(6)
would not apply.
It is also possible to estimate ic from normal
pharmacokinetic models'4 and then make a
comparison of the estimated mean of ic among
subjects in the two groups to assess the appro-
priateness of our proposed methodology. As
the partial pressure of styrene in the lung equi-
librates within a fraction of a second with that
in the alveolar air, the quantity of styrene
entering the pulmonary compartment by
inhalation and venous blood equals that leav-
ing the compartment by exhalation and arter-
ial blood. Therefore, we have:
Q~~C,.3(C)+
Cart(t) = 1=1
Q + Qair Aa/b
(14)
where Ci,,9(t) is the concentration of styrene
in the inhaled air and Q is total cardiac output.
The effective tissue/blood partition coefficient
for each tissue group is the volume weighted
average of each individual tissue partition
coefficient in that group:
(15)
For instance, the lean tissue group in our
model can be divided into two tissue sub-
groups: the blood vessel rich tissues and the
skin and muscle. The volumes of blood vessel
rich tissues and the skin and muscle tissues
have been estimated3 to be 7-1 and 36-3 litres,
respectively, while the tissue/blood partition
coefficients for styrene have been estimated to
be 2-543 and 1.0,'5 respectively. Therefore, we
obtain A, = 1-2 from equation (15). As most
physiological variables cannot be directly mea-
sured on an individual basis, some population
standard values are usually used. Table 3 lists
all those literature based standard values that
are needed in this model. Now, K can be esti-
mated by fitting the model (equation (1), (2),
and (14)) to the experimental data on styrene
concentrations in arterial blood. We find many
possible estimated values for K. The range of
our possible estimates of ic could be as large as
20-fold when allowing those standard values
to vary over reasonable ranges.'6 This undesir-
able phenomenon has been recognised by
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many others-for example, Watanabe et al.'7
As with any compartmental model, the uncer-
tainties associated with these standard values
will necessarily lead to uncertainties about the
key variables. Therefore, valid statistical com-
parisons cannot be made based on these esti-
mated values of K.
The error involved in estimating a from our
data might be large because the observations
were obtained in only two to four hours after
the end of exposure. Ramsey et alt8 monitored
the decay behaviour of styrene in blood of four
male volunteers over 47 hours after exposure
to 82 ppm styrene for six hours. The half life
for the terminal decay phase was measured to
be 13-0 (± 0-7) hours, which translates into an
a value of 0 053 (± 0 003) h-'. These values
are about 1/12 and 1/6 of those we estimated
for the groups with and without previous
exposure to styrene, respectively. Therefore,
the decay constants ofWigaeus et al8 and L6f et
at9 may indeed be too large to represent the
real terminal decay behaviour.
Strictly speaking, equation (8) cannot be
used if a is derived from the decay behaviour
well before equilibrium has been established
throughout the body, including the fat tissues.
This condition is rarely met rigorously in prac-
tice and may constitute the limitation of the
application of this method. However, in the
event that this equilibrium was not achieved in
this study, we think that our conclusion that
styrene exposure did not increase metabolic
activity would still be valid as the shorter
period of observation for the subjects with pre-
vious exposure relative to those without (2 h v
4 h) would have exaggerated the differences in
K values between the two groups (equation
(1 1)).
This result disagrees with that of Ldf et al.9
We think that the main reason for this discrep-
ancy is the higher volume of distribution of
styrene in the pre-exposed subjects due to
their larger amounts of adipose tissue. As we
stated, the decay constants estimated by
Wigaeus et at8 and L6f et at9 were likely to be
more overestimated for the pre-exposed group
than for the group without previous exposure.
As a result, the estimated areas under the
blood concentration v time curves for the two
groups would tend to be significantly different.
However, as the data set is small and as the
data on styrene concentration do not exactly
reflect the true asymptotic decay behaviour,
we think that further studies are needed to
draw more definitive conclusions.
Finally, we will make a few comments about
our estimation of K. Taking a = 0-053 h-' by
Ramsey et alt8 and other data from table 3,
we find from equation (8) and (11) that
K = 0-2/min. Mendrala et at6 measured the
Michaelis-Menten constants Vma,, and K,,,
associated with styrene with human livers in
vitro to be 3-2 mg/h/kg body weight and
0-09 mmol/l, respectively. From equation
(13), this translates into a K value of about
0-2/min when assuming 70 kg body weight
and a liver volume of 1-7 1 (see table 3) for a
standard man. Therefore, our estimate agrees
very well with the experimental results
obtained from human livers in vitro. In con-
trast, K would be 2-57/min by scaling up the
variables for rats,'5 and K could vary anywhere
from 0 1/min to 3-0/min with least squares
methods when allowing 30% variation for the
standard physiological variables. This again
points to the desirability of estimating human
kinetic variables from human data rather than
from extrapolation based on animal experi-
mental data.
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